Innosuisse
VC Fund
Berne, Switzerland
Innosuisse is a VC fund in Berne focused on Health Care and Biotechnology. Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland.
- Total investments:
- 236
- Last investment:
- Lead investor:
- 79%
Last updated:
For AI agents: llms.txt
Industries Innosuisse invests in
Stages Innosuisse invests in
Countries Innosuisse invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $500k–$16M
- Grant
- $41k–$2.5M
- Pre-Seed
- $16k–$4.3M
Investment Focus
Industry
- Health Care 45 (19%)
- Biotechnology 39 (17%)
- Medical Device 31 (13%)
- Medical 30 (13%)
- Software 27 (11%)
Stage
- Grant 184 (78%)
- Pre-Seed 11 (5%)
- Seed 6 (3%)
- Funding Round 1 (0%)
Country
- Switzerland 184 (78%)
- United States 7 (3%)
- United Kingdom 3 (1%)
- Taiwan 1 (0%)
- Germany 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrea Schlapbach
Start-up Coach
|
Start-up Coach | Total investments: 0 | Find email | |
Andreas Jurgeit
Coach and Lecturer
|
Coach and Lecturer | Total investments: 5 | Find email | |
Andre Kudelski
Founder and President
|
Founder and President | Total investments: 0 | Find email | |
Balz Roth
Startup Coach
|
Startup Coach | Total investments: 32 | Find email | |
Carmelo Bisognano
Expert for Innosuisse
|
Expert for Innosuisse | Total investments: 0 | Find email | |
| See all 15 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Actival
|
Actival is driven by innovation and the integration of AI tools in dentistry. It is committed to precision and oral health. | $1.7M / Grant / Jul 20, 2026 | |
Precise Health
|
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to end the threat of antimicrobial resistance through an AI-powered technology. | $1.1M / Grant / Jun 15, 2026 | |
BLEEDnFIRE Therapeutics
|
BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments | Grant / May 27, 2026 | |
OrthoSens
|
OrthoSens develops battery-free sensors that turn standard orthopedic implants into smart, data-driven devices. Unlike existing smart implant solutions that require an implanted battery making them too large and too risky to scale beyond large joints, OrthoSens moves all electronics outside the body. A paper-thin sensor integrates directly intoexisting implants with no battery, no surgical workflow change and zero explant risk. An external wearable powers the sensor wirelessly and collects real-time data on load, micromotion and bone fusion. The result is a footprint 250x smaller than battery-powered competitors, opening up additional spine, foot & ankle markets that existing solutions cannot address. The clinical need is clear: approximately 20% of post-surgical patients drive around 68% of total post-operative costs through missed complications, continuous implant monitoring exists to catch them earlier. Starting January 2026, 745 US hospitals enrolled in CMS's mandatory TEAM bundle are now accountable for 30-day episode costs, creating direct institutional demand for this data.OrthoSens generates revenue through three streams: sensor sales to orthopedic implant manufacturers (unlocking +$1,309 NTAP reimbursement per unit), a SaaS subscription capturing 40% of Medicare's $104/month RPM reimbursement per patient and post-market data analytics. The company has validated its technology across 3 functional prototypes, filed 2 core patents with favorable Freedom to Operate and secured $1.3M+ in non-dilutive funding. It is raising a $2.3M seed round to complete ISO-13485 certification, conduct the FDA pre-clinical study and file a 510(k) submission. The team is led by Gwenael Hannema (3x medtech founder), Dr. Oleg Kotsur (Head of R&D), and key employees, supported by experienced board members with leadership backgrounds at Novartis, Medtronic and J&J MedTech. | $1.1M / Grant / Mar 20, 2026 | |
Chiral
|
Next-generation electronics with nanomaterials | $12M / Seed / Feb 05, 2026 | |
Sparkli
|
Sparkli offers an AI-powered educational platform that turns children’s questions into interactive learning journeys called “expeditions.” The platform generates multimodal content blending visuals, audio narration, games, and quizzes to help learners explore topics and build skills like design thinking, financial literacy, sustainability, andemotional intelligence. It personalizes experiences using generative AI so that young learners engage with content aligned to their curiosity and interests. Sparkli also includes features to track progress and encourage regular engagement through challenges, rewards, and creative reflections. The platform supports both individual exploration and guided learning contexts for children. | Grant / Jan 26, 2026 | |
Reverso Therapeutics
|
Reverso medicines is a biotechnology company that offers therapeutic medicines for anticoagulant therapy. | $901.5K / Grant / Dec 23, 2025 | |
EVis Bioscience
|
EVis Bioscience offers gene delivery solutions using extracellular vesicles, lipid nanoparticles, and hybrid systems. | $391K / Grant / Dec 16, 2025 | |
Lighthouse Tech
|
This pioneering smart eyewear addresses a fast-growing global need: enhancing safety and independence for people who are blind or visually impaired. Using advanced front-facing sensors, TAMI® scans the environment in real time and alerts wearers to obstacles above the waist—areas the white cane cannot cover—unlocking an untapped market segment inassistive mobility. The frame integrates processors, Bluetooth connectivity, and a rechargeable battery seamlessly into the temples. At only 55g, it remains lightweight, waterproof, and impact-resistant, built to withstand sunlight, rain, and snow. This durability ensures consistent performance across geographies, making it suitable for mass adoption. In combination with the white cane, it provides complete protection, positioning the product as a natural complement rather than a replacement. Design is equally strategic. Offered in three sleek models in 4 colors,TAMI® directly challenges the stigma surrounding assistive devices, which are typically bulky or outdated. By making accessibility fashionable, it becomes an attractive lifestyle product, opening the door to broader acceptance and adoption. Onboarding is frictionless: with less than 30 minutes of training, users can operate it confidently. This ease of use accelerates uptake across demographics, including those less familiar with technology. It represents a scalable solution in the assistive tech sector, combining intuitive operation with strong everyday utility. By merging advanced obstacle detection with consumer-driven design, the eyewear sets a new standard in mobility aids. This balance of function and fashion is critical for global scaling, enabling partnerships with established eyewear and healthcare brands while empowering users worldwide with confidence, independence, and social inclusion. | $1.5M / Grant / Dec 02, 2025 | |
Dexterous Endoscopes
|
We are developing endoscopes with variable stiffness, providing high control and advanced tissue dissection capabilities, enabling new types of minimally invasive procedures in sinuses, larynxes, and beyond. | $534.3K / Grant / Dec 01, 2025 | |
| See all 236 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Innosuisse invest in?
Innosuisse invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Grant and Pre-Seed stage. Most of the 236 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Innosuisse's check size?
Innosuisse typically joins rounds of $500k–$16M at Seed, $41k–$2.5M at Grant and $16k–$4.3M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Innosuisse participates in.
How do I contact Innosuisse?
Public channels for Innosuisse include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Innosuisse?
The team at Innosuisse includes Andrea Schlapbach (Start-up Coach), Andreas Jurgeit (Coach and Lecturer) and Andre Kudelski (Founder and President), among 15 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
